MX2016005734A - Citrato férrico para reducir falla cardíaca en pacientes con enfermedad renal crónica. - Google Patents

Citrato férrico para reducir falla cardíaca en pacientes con enfermedad renal crónica.

Info

Publication number
MX2016005734A
MX2016005734A MX2016005734A MX2016005734A MX2016005734A MX 2016005734 A MX2016005734 A MX 2016005734A MX 2016005734 A MX2016005734 A MX 2016005734A MX 2016005734 A MX2016005734 A MX 2016005734A MX 2016005734 A MX2016005734 A MX 2016005734A
Authority
MX
Mexico
Prior art keywords
increase
reduce
iron
patients
ferric citrate
Prior art date
Application number
MX2016005734A
Other languages
English (en)
Spanish (es)
Inventor
Poradosu Enrique
Bentsur Ron
F Oliviero James Iii
Original Assignee
Keryx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keryx Biopharmaceuticals Inc filed Critical Keryx Biopharmaceuticals Inc
Publication of MX2016005734A publication Critical patent/MX2016005734A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2016005734A 2013-11-04 2015-01-29 Citrato férrico para reducir falla cardíaca en pacientes con enfermedad renal crónica. MX2016005734A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361899866P 2013-11-04 2013-11-04
PCT/US2014/063643 WO2015066593A1 (en) 2013-11-04 2014-11-03 Ferric citrate for reducing cardiac failure in chronic kidney disease patients

Publications (1)

Publication Number Publication Date
MX2016005734A true MX2016005734A (es) 2016-11-08

Family

ID=53005244

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005734A MX2016005734A (es) 2013-11-04 2015-01-29 Citrato férrico para reducir falla cardíaca en pacientes con enfermedad renal crónica.

Country Status (15)

Country Link
US (3) US20160256486A1 (enExample)
EP (2) EP3065734A4 (enExample)
JP (3) JP2016535780A (enExample)
KR (1) KR102392441B1 (enExample)
CN (1) CN105873583A (enExample)
AU (1) AU2014341975A1 (enExample)
BR (1) BR112016009901A8 (enExample)
CA (1) CA2928200A1 (enExample)
EA (1) EA201690926A1 (enExample)
HK (1) HK1223031A1 (enExample)
IL (1) IL245317A0 (enExample)
MX (1) MX2016005734A (enExample)
SG (1) SG11201603091QA (enExample)
TW (2) TW202203910A (enExample)
WO (1) WO2015066593A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140016438A (ko) 2009-07-21 2014-02-07 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
RU2728778C2 (ru) 2013-06-05 2020-07-31 Трисида, Инк. Протон-связывающие полимеры для перорального введения
US10172882B2 (en) 2014-06-22 2019-01-08 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
KR102625115B1 (ko) 2014-12-10 2024-01-12 트리시다, 인크. 경구 투여용 양성자-결합 폴리머
IL308673A (en) 2016-05-06 2024-01-01 Tricida Inc Compositions for and method of treating acid-base disorders
SG11202003451UA (en) 2017-11-03 2020-05-28 Tricida Inc Compositions for and method of treating acid-base disorders
CN113613662A (zh) 2018-10-29 2021-11-05 法码科思莫斯控股有限公司 用羧基麦芽糖铁治疗铁缺乏
EA202191858A1 (ru) * 2019-06-12 2021-11-12 Фармакосмос Холдинг А/С Лечение дефицита железа у субъектов с риском нежелательных явлений со стороны сердечно-сосудистой системы и железо для лечения фибрилляции предсердий
CN117999069A (zh) * 2021-05-27 2024-05-07 凯克斯生物制药公司 柠檬酸铁的儿科调配物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE351366B (enExample) * 1965-06-08 1972-11-27 Teikoku Hormone Mfg Co Ltd
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
KR20080037083A (ko) 2005-08-18 2008-04-29 글로보아시아 엘엘씨 약학용 등급의 유기 철 화합물, 그 용도 및 이의 제조 방법
KR20080106506A (ko) * 2006-01-30 2008-12-08 글로보아시아 엘엘씨 만성 신장병의 치료 방법
CN105055446B (zh) 2006-01-30 2022-06-03 宝龄富锦生技股份有限公司 逆转、防止、延迟或稳定软组织钙化的方法
KR20140016438A (ko) * 2009-07-21 2014-02-07 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
ES2547890T3 (es) * 2010-07-07 2015-10-09 Ardelyx, Inc. Compuestos y métodos para inhibir el transporte de fosfato
PL3730136T3 (pl) * 2012-06-21 2024-03-25 Keryx Biopharmaceuticals, Inc. Zastosowanie cytrynianu żelaza(iii) w leczeniu pacjentów z przewlekłą chorobą nerek

Also Published As

Publication number Publication date
US20250360167A1 (en) 2025-11-27
IL245317A0 (en) 2016-06-30
JP2021073230A (ja) 2021-05-13
US20160256486A1 (en) 2016-09-08
EA201690926A1 (ru) 2016-09-30
BR112016009901A8 (pt) 2020-04-14
TWI744215B (zh) 2021-11-01
SG11201603091QA (en) 2016-05-30
CA2928200A1 (en) 2015-05-07
EP3065734A1 (en) 2016-09-14
JP2016535780A (ja) 2016-11-17
TW201609088A (zh) 2016-03-16
AU2014341975A1 (en) 2016-05-19
HK1223031A1 (zh) 2017-07-21
EP3747432A1 (en) 2020-12-09
EP3065734A4 (en) 2017-05-17
US20190307791A1 (en) 2019-10-10
JP6828100B2 (ja) 2021-02-10
CN105873583A (zh) 2016-08-17
KR20160096597A (ko) 2016-08-16
WO2015066593A1 (en) 2015-05-07
TW202203910A (zh) 2022-02-01
KR102392441B1 (ko) 2022-05-02
JP2019206562A (ja) 2019-12-05

Similar Documents

Publication Publication Date Title
MX2016005734A (es) Citrato férrico para reducir falla cardíaca en pacientes con enfermedad renal crónica.
MX2014015615A (es) Uso de citrato ferrico en el tratamiento de pacientes con enfermedad renal cronica.
MX2023000378A (es) Kits, dispositivos descartables para reducir el oxigeno y metodos para usarlos.
UY35313A (es) Antiadhesion de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3
MX2021010528A (es) Metodos y composiciones para el tratamiento de las ulceras.
BR112017016952A2 (pt) terapia de combinação com fatores de coagulação e anticorpos multiespecíficos
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
MX2019005435A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
EA201591424A1 (ru) Способы лечения дефицита железа растворимым пирофосфатом железа
CO6630153A2 (es) Predicción y optimización para terapia sangúínea en falla renal especialmente hemodialisis domiciliaria
PH12015502163A1 (en) Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate, casein phosphopeptide, and protein
EA201590883A1 (ru) Лечение помалидомидом рака у субъекта с почечной недостаточностью
PE20141577A1 (es) Espray para heridas
EA201791611A1 (ru) Лечение пациентов детского возраста с сахарным диабетом 2 типа с помощью ликсисенатида
CL2020000069A1 (es) Mejora de las características del suelo con compuestos lactobionatos.
BR112014009414A2 (pt) uso de micelas de proteína de soro do leite para melhorar o perfil de insulina em pacientes diabéti-cos
Shubina et al. Effect of chronic lead intoxication on formed elements morphology and some biochemical parameters of blood plasma of white rats
Alyavi et al. The Effects of Torasemide on Patients with Chronic Heart Failure
UA62757U (ru) Способ прогнозирования адекватности программного гемодиализа у больных с хронической болезнью почек v стадии
NZ725920A (en) Use of ferric citrate in the treatment of chronic kidney disease patients
ZA202209447B (en) Use of vitamin k in combination with anticoagulants
UA115256U (xx) Спосіб визначення киснево-транспортної енергоструктурної недостатності
UA80889U (ru) Способ дифференциальной диагностики анемий у больных с хроническими заболеваниями внутренних органов
EA202090151A1 (ru) Применение вдыхаемого оксида азота (ii) для лечения легочной гипертензии, связанной с заболеванием легких
RU2011106452A (ru) Способ поперечного пересечения поджелудочной железы